Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough

Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough
Keith Speights, The Motley Fool
·4 min read

It's fair to say that Biogen (NASDAQ: BIIB) is at a pivotal point. It hopes to achieve success in treating Alzheimer's disease but must first jump a major hurdle by winning U.S. Food and Drug Administration (FDA) approval. Biogen announced its first-quarter results before the market opened on Thursday with these factors in the minds of many investors.